Galecto’s Financial Realignment Boosts Investor Confidence Galecto has cut its net loss by $17 million year-over-year, reporting a $21.4 million deficit for 2024. The company’s strategic focus on oncology, highlighted by its acquisition of GB3226, has bolstered its pipeline. Despite challenges, the firm’s streamlined operations and extended cash runway into 2026 are encouraging signs.235